Weed (BUDZ) Other Accumulated Expenses (2019 - 2020)
Weed (BUDZ) recorded quarterly Other Accumulated Expenses of $18500.0 in Q4 2020, up 85.0% quarter-over-quarter from $10000.0 in Q4 2019, and up 85.0% on a YoY basis from $10000.0 in Q1 2020.
Weed (BUDZ) Other Accumulated Expenses (2019 - 2020) Analysis & Trends
Weed's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $18500.0 for Q4 2020.
- In Q4 2020, Other Accumulated Expenses rose 85.0% year-over-year to $18500.0; the TTM figure through Dec 2020 stood at $18500.0 (up 85.0% YoY), while the FY2020 annual figure was $18500.0, up 85.0% from the prior year.
- Other Accumulated Expenses was $18500.0 for Q4 2020 at Weed, up from $10000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $18500.0 in Q4 2020 to a low of $10000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Weed | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 18,500.00 |
| Dec 31, 2019 | 10,000.00 |